Journal Article

DZNE-2026-00313

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Fluoroquinolone-Associated Peripheral and Central Nervous System-Related Disorders: A Large German Claims-Based Cohort Study.

Wicherski, J. ; Peltner, J.DZNE* ; Becker, C. ; Schüssel, K. ; Brückner, G. ; Schlotmann, A. ; Schröder, H. ; Kern, W. V. ; Haenisch, B. (Last author)DZNE*

2026
Wiley-Blackwell Oxford [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1111/ene.70585

Abstract: To examine the association between newly prescribed fluoroquinolones (FQ) and the occurrence of polyneuropathy and certain neuropsychiatric events.German statutory health insurance-based cohort study (2013-2019) of patients exposed to FQ compared to different reference antibiotics. Patients with an incident antibiotic prescription were followed up for 365 days after initial dispensing. Outcomes were defined by incident diagnoses of polyneuropathy/other peripheral nervous system-related diseases (PNS), depression/other affective disorders (DEP), mood-related symptoms (MOOD), somnolence/stupor/coma (SSC), and consciousness-related symptoms (CONSCIOUS). Piece-wise exponential additive mixed models adjusted for person-time, age, comorbidities, year, and quarter of cohort entry were applied.The outcome-specific cohorts included 10.7-14.3 million antibiotic episodes of which 1.7% had incident PNS, 4.8% DEP, 1.5% MOOD, 0.6% SSC, 0.8% CONSCIOUS. Relative risks for these outcomes ranged from 1.04 to 1.10 for FQ versus reference antibiotics. Stratified by gender and age groups, relative risk for PNS was high in ≤ 39-year-old males (aHR = 1.31 [95% 1.19; 1.45]), for MOOD and CONSCIOUS in 40-69-year-old females (aHR = 1.12 [1.08; 1.15], aHR = 1.14 [1.09; 1.19]) for DEP in ≥ 70-year-old males (aHR = 1.16 [1.14; 1.19]), whereas relative risk for SSC was high in ≤ 39-year-old females (aHR = 1.24 [1.10; 1.40]). FQ-associated PNS was mainly comprised of drug-induced polyneuropathy (aHR = 1.68 [1.58; 1.79]). Relative risks for each endpoint varied by choice of active comparator.FQ episodes were associated with an increased risk for neurological and neuropsychiatric events, especially within the first 92 days after initial dispensing. Risk estimates vary by age and gender subgroups.

Keyword(s): Humans (MeSH) ; Female (MeSH) ; Male (MeSH) ; Germany: epidemiology (MeSH) ; Middle Aged (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Cohort Studies (MeSH) ; Fluoroquinolones: adverse effects (MeSH) ; Anti-Bacterial Agents: adverse effects (MeSH) ; Young Adult (MeSH) ; Central Nervous System Diseases: chemically induced (MeSH) ; Central Nervous System Diseases: epidemiology (MeSH) ; Peripheral Nervous System Diseases: chemically induced (MeSH) ; Peripheral Nervous System Diseases: epidemiology (MeSH) ; Adolescent (MeSH) ; Polyneuropathies: chemically induced (MeSH) ; Polyneuropathies: epidemiology (MeSH) ; Mood Disorders: epidemiology (MeSH) ; Mood Disorders: chemically induced (MeSH) ; Aged, 80 and over (MeSH) ; active comparator new user design ; administrative cohort ; adverse drug reactions ; fluoroquinolones ; real‐world data ; Fluoroquinolones ; Anti-Bacterial Agents

---

Contributing Institute(s):

1. Pharmacoepidemiology (AG Hänisch)

Research Program(s):

1. 354 - Disease Prevention and Healthy Aging (POF4-354) (POF4-354)

Appears in the scientific report 2026

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---